The FDA on November 6, 2025, approved DARZALEX FASPRO® for adults with high-risk Smoldering Multiple Myeloma (SMM). DARZALEX FASPRO® is a product of Janssen Biotech, Inc.
Bottom Ad
Advertisement
Subscribe
Top Ad
Advertisement
Advertisement
The FDA on November 6, 2025, approved DARZALEX FASPRO® for adults with high-risk Smoldering Multiple Myeloma (SMM). DARZALEX FASPRO® is a product of Janssen Biotech, Inc.
Advertisement